Lucid Diagnostics expands executive team

Lucid Diagnostics has expanded its executive team with two industry veterans to support its critical market access and direct contracting efforts. Natalie Carfora joins Lucid as VP, Market Access, and James Fricchione as VP, Employer Markets. In conjunction with this expansion, Shaun O’Neil will now serve as Lucid’s President and COO. Natalie Carfora most recently served as Head of Market Access of an innovative molecular diagnostic company focused on commercializing a blood-based test for pancreatic cancer. She previously held market access and commercial roles at Myriad Genetics and Eli Lilly. Jim Fricchione most recently served as Senior Vice President, Sales & Account Management, at Cobalt Benefit Group, a Blue Cross-owned Third-Party Administrator. Shaun O’Neil serves as PAVmed’s Executive Vice President and COO. O’Neil has concurrently served in leadership roles at Lucid since its inception, first as Vice President and Chief Commercial Officer and then as Executive Vice President and Chief Operating Officer since April 2022. Prior to PAVmed and Lucid, O’Neil served in various sales and marketing leadership positions with AngioDynamics.